Antiangiogenic Agent Market size was valued at USD XX Billion in 2024 and is forecasted to grow at a CAGR of ZZ% from 2026 to 2033, reaching USD YY Billion by 2033.
The South Korean market for antiangiogenic agents, crucial in inhibiting the growth of new blood vessels to tumors, has experienced significant growth in recent years. This expansion is primarily driven by the increasing prevalence of cancer and the nation's robust healthcare infrastructure.
In 2024, South Korea's biopharmaceutical market generated revenues of approximately USD 5.86 billion, with projections indicating growth to USD 11 billion by 2030. This growth is expected to occur at a compound annual growth rate (CAGR) of 11.3% from 2025 to 2030. Within this market, monoclonal antibodies emerged as the largest revenue-generating molecule type in 2024, highlighting the importance of targeted therapies, including antiangiogenic agents, in cancer treatment.
Specifically, the ophthalmic drugs segment, which includes anti-VEGF (vascular endothelial growth factor) agents, demonstrated notable performance. In 2024, this market segment generated revenues of USD 715.3 million, with expectations to reach USD 1.28 billion by 2030, reflecting a CAGR of 10.3%. Anti-VEGF agents were the largest and fastest-growing drug class within this segment, underscoring their critical role in treating retinal diseases and certain cancers.
The demand for antiangiogenic agents is also influenced by the aging population. Between 2013 and 2022, the number of patients prescribed anticancer drugs increased at a CAGR of 3.1%, with expenditures rising from USD 584.2 million to USD 1.57 billion. Notably, patients aged 65 and older accounted for 47.2% of these expenditures by 2022, emphasizing the need for effective treatments for age-related ailments, including cancer.
Major pharmaceutical companies, both domestic and international, are actively contributing to this market's expansion. Companies such as AbbVie Inc., AstraZeneca PLC, Bayer AG, and Samsung Pharm Co. Ltd. are leading players, engaging in acquisitions and joint ventures to strengthen their positions in the South Korean market. Their efforts are pivotal in introducing innovative antiangiogenic therapies to meet the growing demand.
In summary, the South Korean antiangiogenic agent market is poised for substantial growth, driven by technological advancements, an aging population, and strategic industry collaborations. This growth presents significant opportunities for stakeholders to address the evolving needs of cancer patients through effective and accessible therapies.
Get an In-Depth Research Analysis of the South Korea Antiangiogenic Agent Market Size And Forecast [2025-2032]
CancerIndex
Regeneron
Bayer
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the South Korea Antiangiogenic Agent Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the South Korea Antiangiogenic Agent Market
Small Molecule Inhibitors
Monoclonal Antibodies
Soluble Receptors
Peptides and Proteins
Gene Therapy Products
VEGF Inhibitors
Thrombospondin-1
Integrin Inhibitors
Angiopoietin Inhibitors
Histone Deacetylase Inhibitors
Cancer Treatment
Diabetic Retinopathy
Age-related Macular Degeneration (AMD)
Psoriasis
Other Vascular Diseases
Oral Administration
Intravenous Administration
Subcutaneous Administration
Topical Administration
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Specialty Pharmacies
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
For More Information or Query, Visit @ South Korea Antiangiogenic Agent Market Research Analysis
1. Introduction of the South Korea Antiangiogenic Agent Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. South Korea Antiangiogenic Agent Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. South Korea Antiangiogenic Agent Market, By Type
6. South Korea Antiangiogenic Agent Market, By Application
7. South Korea Antiangiogenic Agent Market, By Geography
Asia-Pacific
China
Japan
Korea
India
Australia
Indonesia
Thailand
Philippines
Malaysia and Vietnam
8. South Korea Antiangiogenic Agent Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/